Kura Oncology (NASDAQ:KURA) Releases Earnings Results, Misses Estimates By $0.20 EPS

Kura Oncology (NASDAQ:KURA) posted its quarterly earnings data on Thursday. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20), FiscalAI reports. Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 91.62%. The firm had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million.

Here are the key takeaways from Kura Oncology’s conference call:

• Komzifti launched after FDA approval and generated $2.1M in late?2025 revenue, with rapid uptake: ~84% of private payers established coverage within 90 days, a two?day average prescription?to?payer decision via KuraConnect, and some payers implementing step edits that require Komzifti before a competitor.
• Komzifti is listed in the FDA Orange Book with patent protection through July 2044, which the company says strengthens the long?term value of the franchise as it expands into frontline and combination settings.
• Kura is executing an extensive development plan—pivotal KOMET?017 (two independently powered frontline trials), multiple combination programs (venetoclax, FLT3 inhibitors), and solid?tumor efforts including darlifarnib—with multiple data readouts planned in 2026 and a phase?3 top?line readout expected in 2028.
• Commercial launch and expanded development increased costs: Q4 2025 net loss widened to $81M (vs. $19.2M a year earlier), with higher R&D ($64.4M) and SG&A ($39.1M) contributing to the loss.
• Kura ended 2025 with $667.2M in cash and short?term investments and expects collaboration revenue and ~<$180M in anticipated milestones to fund its ziftomenib AML program through the first KOMET?017 phase?3 results in 2028.

Kura Oncology Stock Up 5.3%

Shares of NASDAQ KURA opened at $8.96 on Friday. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 0.02. The firm has a market cap of $779.70 million, a PE ratio of -2.82 and a beta of 0.22. The company’s fifty day simple moving average is $8.75 and its 200 day simple moving average is $9.39. Kura Oncology has a 12-month low of $5.41 and a 12-month high of $12.49.

Key Stories Impacting Kura Oncology

Here are the key news stories impacting Kura Oncology this week:

• Positive Sentiment: KOMZIFTI early commercial traction — management reported $2.1M in net product revenue from ~5 weeks of sales and rapid payer coverage (~80% of private payers aligned to label), supporting near-term uptake expectations. Q4 & Corporate Update
• Positive Sentiment: Material milestone payments & cash runway — Kura recorded collaboration revenue and milestone receipts (including a reported $135M channel milestone and additional $30M payments tied to Phase 3 dosing) and ended 2025 with $667.2M cash plus ~$180M anticipated collaboration payments, which management says funds operations into pivotal Phase 3 topline results. This reduces near?term financing risk. Q4 Financials
• Neutral Sentiment: Pipeline cadence: management flagged multiple 2026 data readouts and enrollment progress (pivotal KOMET?017 frontline trials, KOMET?007 combos, FIT?001 expansion). These are potential future catalysts but carry binary clinical risk. Corporate Update
• Neutral Sentiment: Inducement grants: the company issued options for 44,700 shares to four new hires under Nasdaq rules — modest potential dilution and a routine hiring incentive. Inducement Grants
• Negative Sentiment: Q4 earnings and revenue miss — Kura reported a $0.92 loss per share vs. consensus -$0.72 and Q4 revenue of $17.3M vs. est. ~$34.7M. R&D and SG&A rose sharply, driving a wider net loss ($81M). These miss metrics explain selling pressure despite commercial progress. Earnings Recap
• Negative Sentiment: Safety profile and boxed warning remain material risks — differentiation syndrome, QTc prolongation and other serious AEs were highlighted in the label and trial experience; these safety issues can limit uptake, dosing, and label expansion. Safety & Label
• Negative Sentiment: Analyst note: Wedbush trimmed its price target from $38 to $36 (rating remains Outperform), a modest downgrade that may temper upside sentiment despite bullish coverage from other firms. Analyst Update

Insider Transactions at Kura Oncology

In other news, insider Teresa Brophy Bair sold 11,208 shares of the stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total transaction of $94,819.68. Following the transaction, the insider owned 226,931 shares of the company’s stock, valued at $1,919,836.26. This represents a 4.71% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Brian T. Powl sold 6,414 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $54,262.44. Following the completion of the sale, the insider owned 183,275 shares of the company’s stock, valued at approximately $1,550,506.50. This represents a 3.38% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 59,794 shares of company stock valued at $537,176. 6.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC grew its stake in Kura Oncology by 5.7% in the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after acquiring an additional 459,422 shares during the period. Vanguard Group Inc. increased its holdings in shares of Kura Oncology by 2.2% during the third quarter. Vanguard Group Inc. now owns 5,468,522 shares of the company’s stock valued at $48,396,000 after acquiring an additional 120,197 shares in the last quarter. State Street Corp raised its position in shares of Kura Oncology by 47.5% during the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock worth $51,234,000 after purchasing an additional 1,587,959 shares during the period. AQR Capital Management LLC raised its position in shares of Kura Oncology by 36.6% during the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock worth $31,816,000 after purchasing an additional 820,020 shares during the period. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Kura Oncology by 101.6% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,224,590 shares of the company’s stock worth $19,688,000 after purchasing an additional 1,121,228 shares in the last quarter.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. Zacks Research raised shares of Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Wall Street Zen downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. UBS Group lifted their price objective on Kura Oncology from $14.00 to $16.00 and gave the stock a “buy” rating in a research report on Friday, November 14th. Leerink Partners set a $20.00 price objective on Kura Oncology and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Finally, Citigroup restated a “market outperform” rating on shares of Kura Oncology in a research report on Friday, December 5th. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Kura Oncology presently has an average rating of “Moderate Buy” and an average target price of $27.71.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.